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A B S T R A C T
Autoinﬂammatory diseases occupy one of a group of primary immunodeﬁciency diseases that are generally
thought to be caused by mutation of genes responsible for innate immunity, rather than by acquired immunity.
Mutations related to autoinﬂammatory diseases occur in 12 genes. For example, low-level somatic mosaic
NLRP3 mutations underlie chronic infantile neurologic, cutaneous, articular syndrome (CINCA), also known as
neonatal-onset multisystem inﬂammatory disease (NOMID). In current clinical practice, clinical genetic testing
plays an important role in providing patients with quick, deﬁnite diagnoses. To increase the availability of such
testing, low-cost high-throughput gene-analysis systems are required, ones that not only have the sensitivity to
detect even low-level somatic mosaic mutations, but also can operate simply in a clinical setting. To this end, we
developed a simple method that employs two-step tailed PCR and an NGS system, MiSeq platform, to detect
mutations in all coding exons of the 12 genes responsible for autoinﬂammatory diseases. Using this amplicon
sequencing system, we ampliﬁed a total of 234 amplicons derived from the 12 genes with multiplex PCR. This
was done simultaneously and in one test tube. Each sample was distinguished by an index sequence of second
PCR primers following PCR ampliﬁcation. With our procedure and tips for reducing PCR ampliﬁcation bias, we
were able to analyze 12 genes from 25 clinical samples in one MiSeq run. Moreover, with the certiﬁed primers
designed by our short program—which detects and avoids common SNPs in gene-speciﬁc PCR primers—we
used this system for routine genetic testing. Our optimized procedure uses a simple protocol, which can easily be
followed by virtually any oﬃce medical staﬀ. Because of the small PCR ampliﬁcation bias, we can analyze
simultaneously several clinical DNA samples with low cost and can obtain suﬃcient read numbers to detect a
low level of somatic mosaic mutations.
1. Introduction
There are many similar diseases that present clinically with fever
and inﬂammation, and many of these occur due to gene mutations.
Traditionally, identifying disease-causing gene mutations has been
time-consuming and costly, requiring patient samples to be analyzed
by a specialized laboratory employing sophisticated equipment. In
recent years, however, a push is being made to make genetic testing
available in clinical practice, in settings wherein doctors can quickly
determine whether the patients in front of them have a mutation of
genes known to underlie certain diseases. This type of clinical genetic
testing plays an indispensable role in providing patients with quick,
deﬁnite diagnoses. In order to reduce the economic burden on patients,
clinical genetic testing must be performed accurately and quickly at a
relatively low cost.
A general trend in Next Generation Sequencing (NGS) platforms is
a move from the Roche GS 454 (its manufacturer no longer oﬀers
technical support) to the Illumina HiSeq. Development of a simple,
accurate, and high-throughput method is embodied by the MiSeq
platform. Presently, many kits are commercially available, but they are
still too expensive for routine sequencing. A signiﬁcant contributor to
the cost of genetic testing is labor costs. Most currently used sequen-
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cers require highly trained technicians to analyze patient samples and
operate sequencers. As labor costs occupy a large percentage of the
total cost of genetic testing, it cannot be completely ignored when
considering the overall cost of genetic testing. Introducing a simple
testing protocol would be most eﬀective in reducing labor costs,
because it would eliminate complicated and extensive training neces-
sary for a technician to become suﬃciently skilled to prepare, analyze,
and run samples. This would be especially helpful for genetic diseases
that physicians are beginning to see more frequently in the clinic.
Autoinﬂammatory diseases are a relatively new category of disease
proposed in 1999 and are thought to be caused by mutations of genes
involved in the innate immune system, but generally not in the
adaptive immune system. Autoinﬂammatory diseases often are char-
acterized by recurrent fever and inﬂammation. Almeida de Jesus and
Goldbach-Mansky have categorized these into six groups based on
clinical manifestations [1]. Familial Mediterranean Fever (FMF); TNF
receptor-associated periodic syndrome (TRAPS); mevalonate kinase
deﬁciency (MVK)/hyperimmunoglobulinemia D with periodic fever
syndrome (HIDS); cryopyrin-associated periodic syndromes (CAPS);
neonatal-onset multisystem inﬂammatory disease (NOMID)/chronic
infantile, neurological, cutaneous; and articular (CINCA) syndrome are
all examples of autoinﬂammatory diseases. Somatic mosaicism of
NLRP3 in patients with CINCA have been reported [2–5].
Clinical genetic testing should be performed carefully because
autosomal dominant gain of function mutations are reported in many
of these autoinﬂammatory diseases. Moreover, it is not known exactly
whether somatic mutations other than those in NLRP3 confer one of
the autoinﬂammatory diseases.
We have chosen two-step tailed PCR ampliﬁcation and amplicon
sequencing for library preparation for the MiSeq platform for ﬁve
reasons. Firstly, around 10 genes have been generally estimated as
being candidate genes responsible for autoinﬂammatory diseases based
on symptoms associated with these diseases. Secondly, new target
genes will likely be added as this ﬁeld of study continues to progress.
Even if one made custom-ordered probes or capturing probes for all
target genes simultaneously, researchers will want additional probes
for newly discovered responsible genes in the future. It is costly to
custom order a new set of probes again, because commercially available
systems generally do not support small additions and changes to
existing probes. Thirdly, high sensitivity and suﬃcient read depth are
necessary in order to detect somatic mosaic mutations. Fourthly, as
simple a procedure as possible is desirable. Lastly, costs need to be
reduced. Motivated by these ﬁve reasons, we attempted to simulta-
neously analyze several clinical DNA samples on one MiSeq run,
aiming to decrease PCR ampliﬁcation bias as much as possible.
2. Materials and methods
2.1. Patients and clinical diagnosis
A total of 108 patients having an autoinﬂammatory disease
diagnosis were consecutively diagnosed and recruited at the
Department of Pediatrics, Kyoto University Graduate School of
Medicine. All of the patients were Japanese and provided written
informed consent (below) for inclusion in the high-throughput sequen-
cing analysis.
2.2. Ethics statement
All patients provided written informed consent after we gave them a
full explanation of the study. All patients gave us explicit permission to
analyze their DNA sequencing data for genes responsible for autoin-
ﬂammatory diseases. This study was approved by both the Human
Research Ethics Committee of the University of Kyoto and the Kazusa
DNA Research Institute.
2.3. DNA samples
DNA samples were de-identiﬁed with regard to subjects’ personal
information. DNA from patients' blood was puriﬁed using a QIAamp
DNA blood kit (QIAGEN, Venlo, Netherlands). Before use, DNA
samples were quantiﬁed by Qubit Fluorometric quantitation (Thermo
Fisher Scientiﬁc, Waltham, MA, USA).
2.4. Design PCR primers
Primers were basically designed by ExonPrimer Perl script (https://
ihg.helmholtz-muenchen.de/ihg/ExonPrimer.html). The design input
parameters were 30 bp, 150 bp, and 20 bp for the minimal distance
between the primer and exon/intron boundary, maxima target size,
and overlap, respectively. The standard values were selected according
to the parameters of Primer3Web options (http://bioinfo.ut.ee/
primer3/) [6].
ExonPrimer suggested candidate paired PCR primers. We wrote a
short custom program to detect common SNPs in the DNA sequence of
candidate PCR primers. This program consulted the UCSC In Silico
PCR database (http://rohsdb.cmb.usc.edu/GBshape/cgi-bin/hgPcr)
and the dbSNPs database (dbSNP 135). We named this short
program "Primer-dbSNP search" (i.e., SNPs ﬁnder for PCR primers).
After checking common SNPs using Primer-dbSNP search, we re-
designed undesirable primers to avoid common SNPs using
commercially available oligo 6.0 Primer Analysis Software (Molecular
Biology Insights, Inc., Colorado Springs, CO, USA). M13FW (5′-
TGTAAAACGACGGCC −3′) and M13RV (5′- GGAAACAGCTATGAC
−3′) were added at the 5′ end of each forward and reverse primer,
respectively. Primers were synthesized by Euroﬁns Genomics K.K.
(Tokyo, Japan).
2.5. Library preparation following multiplex PCR
Supplemental Table 1 lists 234 PCR primer pairs used to target the
protein coding region and a minimum of 20 bp of untranslated,
ﬂanking intronic region of the genes. Dual-indexed secondary PCR
primers are described in Fig. 1. For the ﬁrst PCR ampliﬁcation,
ampliﬁcation was performed in a 0.2 ml 8-strip PCR tube (Corning,
Corning, NY, USA) in a ﬁnal volume of 50 μl. It had 25 μl of 2 X
Multiplex PCR Buﬀer (Mg2+, dNTP plus) (TAKARA, Multiplex PCR
Assay Kit Ver. 2); 0.25 μl of Multiplex PCR Enzyme Mix; each gene-
speciﬁc primer pool (0.05 μM); and 400 ng of human genomic DNA.
The following ampliﬁcation steps were performed: 94 °C for 1 min, 10
cycles at 94 °C for 30 s, and 60 °C for 1 min, followed by incubation at
72 °C for 10 min. The resulting PCR products were puriﬁed twice with
AMPureXP beads (Beckman Coulter Inc., Brea, CA USA). To minimize
accidental cross-contamination between samples, we puriﬁed the PCR
product using a low-binding tube, not a 96-well plate. Typically, 10 ng
of puriﬁed PCR product was used for each PCR step. This is equivalent
to using only one-third of the eluate from AMPureXP puriﬁcation. For
secondary PCR ampliﬁcation, ampliﬁcation was performed in a ﬁnal
volume of 50 μl. It had 25 μl of 2 X Multiplex PCR Buﬀer (Mg2+, dNTP
plus) (TAKARA, Multiplex PCR Assay Kit Ver. 2); 0.25 μl of Multiplex
PCR Enzyme Mix; each index primer (10 μM; each D501-D508-like
and D701-D712-like Dual-indexed secondary PCR primers); and 10 ng
of puriﬁed PCR product. The following ampliﬁcation steps were
performed: 94 °C for 1 min, 5 cycle at 94 °C for 30 s, 55 °C for 10 s,
and 72 °C for 30 s, followed by incubation at 72 °C for 10 min. The PCR
product was puriﬁed twice with AMPureXP beads using non-skirted
thin-wall 96-well 0.2 ml plates. The puriﬁed PCR product was quanti-
ﬁed with the Kapa Library Quantiﬁcation Kit for the Illumina NGS
(Kapa Biosystems, Wilmington, MA, USA), using an ABI 7900HT Fast
Real-Time PCR System (Thermo Fisher Scientiﬁc). After quantiﬁcation,
we typically mixed equal molar concentrations of PCR product from 25
individual DNA samples, applied it to MiSeq using the MiSeq Reagent
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kit v3 600 cycles (Illumina, San Diego, CA, USA) according to the
manufacturer's instructions. In line with the so-called DarkCycle
procedure, we did not collect data for the ﬁrst 15 cycles, because the
ﬁrst 15 bp are common sequences containing M13FW and M13RV
DNA sequences in R1 and R2 reads, respectively.
2.6. Data analysis
Each PCR primer sequence at the 5′ terminus of the read sequence
was trimmed from the sequence read data, and each PCR primer and
additional M13FW or M13RV 15-mer sequence in the 3′ terminus of
the read sequence were also trimmed from the sequence read data by
the software Cutadapt [7]. Low quality sequences, namely low quality
25 (Q25) from the 3′ terminus of the read sequence were trimmed from
the sequence read data without the primer sequence using the software
sickle [8]. The software's quality ﬁlter removes the R1 and R2 reads,
which contain low quality sequences at a high ratio. The software
Sommelier, described previously [5], is a variant caller program that
includes Blat software [9] as a component. Trimmed sequence read
data were mapped onto DNA sequence data of the amplicon derived
from the human reference genome (hg19) using Blat and default
parameters. Variants, which were identiﬁed by Sommelier, were
annotated using a short program (proc_exome_mutation_b37.v4.pl).
After manual curation, all missense, nonsense, and frame-shift muta-
tions, as well as other severe mutations, were conﬁrmed by Sanger
sequencing using BigDye Terminator v3.1 (Thermo Fisher Scientiﬁc)
Fig. 1. Schematic diagram illustrating our MiSeq approach to identifying genes responsible for autoinﬂammatory diseases. (A) First gene-speciﬁc primer and second primer for two-step
tailed PCR. For the ﬁrst PCR ampliﬁcation step, the ﬁrst PCR primer was composed of M13FW 15mer and a gene-speciﬁc primer, and M13RV 15mer and gene-speciﬁc primer. For the
second ampliﬁcation step, the second PCR primer (forward orientation) was composed of P5, an index tag, an R1 seq primer, and an M13FW DNA sequence. The second PCR primer
(reverse orientation) was composed of P7, an index tag, an R2 Seq primer, and an M13RV DNA sequence. (B) Scheme of clinical genetic testing using the MiSeq platform. All coding
exons from the nine genes analyzed in this study were ampliﬁed simultaneously by multiplex PCR in one tube. After the second PCR ampliﬁcation step, index tags were added to
distinguish 25 individual samples. After the MiSeq run, the resulting data were demultiplexed using the index tags. Sequencing data were analyzed in silico. The software program
Sommelier detects variants and creates a ﬁle annotating identiﬁed variants. After manual curation, important mutations, e.g., missense mutations, were conﬁrmed by Sanger DNA
sequencing.
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and ABI 3130 or 3710 instruments (Thermo Fisher Scientiﬁc).
3. Results and discussion
As illustrated in Fig. 1A, we chose two-step tailed PCR for high-
throughput analysis using the Next Generation Sequencing platform,
MiSeq, to detect variants in several clinical DNA samples. Because the
read number obtained in one MiSeq run is limited and cannot be
increased easily, we sought to minimize bias of PCR ampliﬁcation and
deviation of read number of each amplicon by analyzing several DNA
samples simultaneously.
First, we selected nine genes (IL1RN, MEFV, MVK, NLRP12,
NLRP3, NOD2, PSMB8, PSTPIP1, and TNFRSF1A) associated with
autoinﬂammatory diseases, and made a total of 160 primer pairs.
These nine genes contain 88 coding exons. Since large exons need
multiple primer pairs, we made 320 primers for PCR ampliﬁcation. At
present, the maximum read length of MiSeq is 300 bp (2×300) for
paired-end sequencing, since our criteria for clinical genetic testing is
that each base should be read in both directions. Large coding exons
completely overlapped with some amplicons derived from split exons.
These gene-speciﬁc PCR primers contained an additional common
15 bp of M13FW and M13RV sequence in the 5′ terminus to be
ampliﬁed during secondary PCR ampliﬁcation.
Multiplex PCR was performed in one tube using all gene-speciﬁc
primers. Because PCR ampliﬁcation bias increases during each step of
the PCR cycle, in our protocol we performed 10 cycles for the ﬁrst PCR
ampliﬁcation and 5 cycles for the second PCR ampliﬁcation. Various
PCR ampliﬁcation parameters were assessed during preliminary ex-
periments in order to determine the optimal conditions (i.e., the
number of PCR cycles, the concentration of each PCR primer in the
reaction, and the annealing temperature) for the gene-speciﬁc primer
sets for the nine genes responsible for autoinﬂammatory diseases (see
Methods). We noticed that performing the AMPureXP puriﬁcation
produced better results for MiSeq DNA sequencing, since small PCR
products derived from primer dimers produce many empty sequence
reads, which waste large volumes of limited and valuable read numbers
in MiSeq.
Secondary PCR ampliﬁcation was performed to add an index
sequence distinguishing each PCR product derived from each clinical
DNA sample. Typically, the indexed PCR product derived from the 25
individual DNA samples were mixed and applied to one MiSeq run.
After a MiSeq run, sequencing data were demultiplexed by using the
index sequence, PCR primer sequences and low quality regions were
trimmed, and sequence reads containing low-quality sequences were
removed. This was accomplished using the variant call software
Sommelier, which calls variants from the trimmed sequence read data
and writes a user-friendly ﬁle containing a variant list with annotation
information in Excel format.
Supplemental File 2 shows typical clinical genetic testing results for
autoinﬂammatory diseases. Sheet 1, “Read Count” of Supplementary
File 2 shows the read number of each amplicon. These indicate that
there are enough read numbers in each amplicon. The average read
number for forward and reverse orientation is 4583 and 4469,
respectively. The rate of over 20 reads for both orientations is 100%.
The rate of over 30 and 100 reads in both orientations are 99.79% and
98.95%, respectively. Moreover, total read numbers, or the sum of
forward and reverse read numbers for each amplicon, are shown in
Fig. 2. Average total read number of each amplicon was 9052. The
average minimum read number and maximum read number was 405
and 32434, respectively. The ratio of the average maximum read
number to average minimum read number was 79.94. We observed
that the total read number in some amplicons was relatively small, and
they contained an unusually high GC-rich region. PCR ampliﬁcation
bias is unavoidable for such extremely GC-rich regions. In conclusion,
in our multiplex experimental condition, PCR ampliﬁcation bias is low,
which permits parallel analysis of many clinical samples.
The read number for each amplicon in Fig. 2 and Supplemental File
2 relates to the average depth of each exon; that is, the quotient is total
base number derived from all read numbers divided by base number of
the exon. Because large exons were covered by sequence reads of some
overlapping amplicons and gaps in exons, special attention was
required, especially for large exons. The read depth for each base was
completely checked for all coding exons of the targeted genes. When no
gaps are present in the coding exons, MiSeq achieves suﬃcient read
depth for each base. For regions sequenced at a depth greater than 25,
the depth coverage was 100%; for those sequenced at a depth greater
than 30, the depth coverage was 99.98%. These results showed that
amplicon sequencing with suﬃcient depth was performed.
Sheet 2 of Supplementary File 2 (Final Results sheet) shows a list of
mutations identiﬁed using the MiSeq platform. The list contains
Fig. 2. Read number comparisons for each amplicon derived from multiplex PCR ampliﬁcation. Most amplicons were read over 1000 times. The average read number was 9052.
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genome position, gene symbol, mutation type, frequencies for forward
orientation and for reverse orientation, coding DNA sequence (CDS)
level change, protein level change, AA variation, dbSNPs, and allele
frequency in dbSNPs for each mutation. Such variants lists that contain
annotation information are very easy to use, especially when many
genes and many clinical samples are analyzed simultaneously.
In the on-going scientiﬁc discussion about the sequence of PCR
products, especially those concerning exome sequencing using the
capture method, the view is sometimes espoused that artiﬁcial muta-
tions are incorporated during PCR ampliﬁcation. However, we believe
this is not relevant in the case of our approach for the following
reasons. First of all, we used 400 ng of human DNA, which is
equivalent to 1.3×105 copies of the haplotype, which translates to an
average read number of about 9000 per amplicon. This read depth is
suﬃcient enough so that one can ignore any rare, artiﬁcial mutations
that theoretically can occur during PCR ampliﬁcation. Because our PCR
products were derived from ampliﬁcation of an independent template
of 1.3×105 copies, even if misincorporation did occur during the ﬁrst
PCR ampliﬁcation step, its eﬀect would have been extremely small or
negligible.
Frequency of variants is an important numerical aspect for deter-
mining whether a mutation is a homozygous or heterozygous mutation.
In the early stages of this study, we noticed a case that had a variant
frequency of less than 12% in one amplicon of a sample from one
patient. Sanger DNA sequencing revealed that genomic DNA corre-
sponding to the gene-speciﬁc PCR primer, by chance, contained a SNP.
The presence of an accidental SNP in a gene-speciﬁc PCR primer
causes a one-base mismatch between the PCR primer and the DNA
template. In heterozygotes, the DNA template from one allele hybri-
dizes with the primer completely. On the other hand, a DNA template
with a SNP hybridizes with the mismatch. Therefore, PCR ampliﬁcation
eﬃciency is much lower in cases of mismatch than it is when the PCR
primer and DNA template complete match. Fig. 3 shows the relation-
ship between the location of a mismatch in a PCR primer and the
detection frequency of a variant allele containing a SNP. As expected, a
SNP near the 3′ end of the primer greatly aﬀects the detection
frequency of the variant. Especially having a SNP at the ﬁrst and
second base position in a PCR primer signiﬁcantly decreases the
detection frequency by 1–2%.
Although SNPs very rarely occur in gene-speciﬁc PCR primers,
because we plan to analyze genes of several hundred patients, we took
countermeasures to reasonably guard against this problem. We wrote a
short program to detect SNPs in gene-speciﬁc PCR primers. When
common SNPs ( > 1% frequency) were detected in a PCR primer, the
PCR primer was re-designed to avoid SNP sites. Completely new PCR
sets void of common SNPs were used in subsequent MiSeq experi-
ments.
Our genetic testing using MiSeq also detected large deletions in X-
chromosome-linked genes from a patient (data not shown; manuscript
in preparation) on other similar panel sets for primary immunodeﬁ-
ciency diseases, but not on the panel we used for the present study to
examine autoinﬂammatory-disease-causing genes. The signiﬁcant de-
crease in read number of the amplicon indicates the deletion of the
exon(s). In fact, we did conﬁrm that this was due to a large deletion in
the patient's genome.
Next, we tried to detect mosaic mutations using our MiSeq
detection system. In the ﬁrst model experiments, two DNA samples
with diﬀerent SNPs were mixed at a rate of 5% and 10%, respectively.
This mixed DNA sample was used for our MiSeq experiment. When a
SNP in the material was a heterozygote, as expected we detected nearly
2.5% and 5% of variant frequency. This demonstrates that variant
frequency values derived from our system are extremely precise. In the
next experiment involving the detection of mosaic mutations, we tested
three real DNA samples, which were identiﬁed to have somatic mosaic
mutations. As shown in Table 1, our MiSeq experiment detected 35.3%,
7.0%, and 6.3% of the variant frequency of these samples.
Next, we tested whether we could add the primers of three other
genes onto the nine-gene panel used for our MiSeq experiment. The
gene-speciﬁc primers of three genes, NLRC4, PLCG2, and HMOX1,
were designed according to the procedure described above. We took
special precautions to avoid accidental incorporation of common SNPs
into the designed candidate primers. PCR primer pairs of 74 amplicons
derived from 45 coding exons in these three genes were added to the
pool of PCR primers used for the previously identiﬁed nine genes
responsible for autoinﬂammatory diseases. Addition of the three new
primer pairs did not negatively aﬀect the accuracy of genetic testing
using our MiSeq system. Indeed, our system is suﬃciently robust and
ﬂexible that it could accommodate changes, such as the addition of
these three genes. One strong advantage this system has in terms of
clinical genetic testing is its ﬂexibility, which would be especially useful
for relatively “new” syndromes like autoinﬂammatory diseases. These
diseases have only recently been recognized, and as they receive more
attention from the scientiﬁc community, likely more responsible genes
will be identiﬁed and will need to be characterized.
The mutations that we found in this study are summarized in
Table 2. Twenty-seven missense mutations emerged from the 108
patients examined. The most notable of these were Gly566Ala in
NLRP3, Lys34Thr and Asp369Gly in PSTPIP1, Arg410His and
Pro115Arg in MEFV, and Gln902Lys in NOD2, which have not been
reported previously. All missense mutations identiﬁed in this study
were conﬁrmed by Sanger sequencing. Independent DNA sequencing
using gold-standard methods, such as Sanger sequencing, validates the
reliability of clinical genetic testing using the MiSeq system in
identifying mutations. In addition, independent DNA sequencing
would identify any errors that may have arisen from, for example, a
technician inadvertently mixing up patient samples.
In some of the samples we analyzed, we did not detect any
mutations in genes that were identiﬁed previously to cause autoin-
ﬂammatory diseases [1]. This suggests that not all responsible genes
were included in our PCR-primer sets, because some genes responsible
for autoinﬂammatory diseases have not been identiﬁed yet. Our aim,
therefore, is to broaden our ability to test for more autoinﬂammatory
disease-associated genes simultaneously using our MiSeq platform.
In the present study, we noticed that MiSeq had some tendencies
that could lead to inaccurate results if not ﬁxed via in silico analysis.
First, in the eight serial thymine (T) cluster, we often observed artiﬁcial
T deletions, at an approximate frequency of 2%. Second, mis-synthe-
sized PCR primers were often detected as noise in the analysis. The
DNA synthesizer we used never produced 100% exact oligomers.
Rather, it mis-synthesized a very small volume of product. Moreover,
cutadapt software hardly ever detected and trimmed PCR primers
containing a mutation. Thus, the noise derived from mis-synthesized
primers should be removed during in silico analysis. Fourth, pseudo
genes, gene families, and repeat sequences located extremely close to
an exon can lead to the production of false amplicons during PCR,
which, when ampliﬁed, produce noise reads. False mapping was
detected as noise. Such false mapping should also be removed by in
silico analysis.
In our MiSeq approach, the primer design step is one of the most
important steps to ensure successful multiplex PCR ampliﬁcation with
minimal PCR ampliﬁcation bias. PCR primers that overlap each other
must be avoided, above and beyond the need to make good PCR
primers.
Exome analysis can survey mutations in all exons without one
knowing ahead of time the genes responsible for any given disease. At
the present time, however, exome analysis remains expensive and has a
relatively low read number. Indeed, with a small read depth, even the
MiSeq platform cannot distinguish true mutations from misreads and
surely cannot detect low frequencies of somatic mosaic mutations.
Our MiSeq approach is suitable for routine clinical genetic testing.
If our MiSeq approach does not detect a signiﬁcant mutation, if
necessary, additional analysis (e.g., exome analysis) should be per-
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formed. We are currently developing another gene panel for the MiSeq
platform in order to analyze another category of primary immunode-
ﬁciency disease. Along this line, we are developing a system to analyze
simultaneously over one thousand amplicons of 57 genes that confer
primary immunodeﬁciency diseases, although we need to reduce PCR
ampliﬁcation bias and diﬀerences in read number in NGS.
Table 1
Detection of somatic mosaic mutations in patient DNA using our MiSeq analysis system.
Patient ID Genome Position Gene Symbol Fwd Freq Rev Freq Fwd Read Rev Read Region CDS Level Change AA Variation dbSNP
11028IS chr1:247587751 NLRP3* 35.767 34.922 4985 2643 exon3e c.1000 A >G p. Ile334Val –
11040GM chr1:247588450 NLRP3* 7.161 7.226 5837 4954 exon3i c.1699 G > A p. Glu567Lys rs104895389
11040GM chr1:247588450 NLRP3* 6.758 7.068 5993 3551 exon3j c.1699 G > A p. Glu567Lys rs104895389
12039IA chr1:247588450 NLRP3* 6.603 6.141 6542 5699 exon3i c.1699 G > A p. Glu567Lys rs104895389
12039IA chr1:247588450 NLRP3* 6.127 6.286 7002 4216 exon3j c.1699 G > A p. Glu567Lys rs104895389
In “Regions” having large exons, the exons were overlapped by amplicons. Letter after exon number indicates the name of each amplicon. The names of the amplicons are identical to the
names of the corresponding primers, as shown in Additional File 1. Amplicons, exon3i, and exon3j were independently amplified, sequenced, and analyzed.
* In NLRP3, the clinical genetics community typically uses the second Met as the initial start site, not ﬁrst the Met. Thus, in this study, NLRP3 had two additional amino acids because
the ﬁrst Met was used for the annotation of the NLRP3 gene.
Fig. 3. Eﬀect of amplicon read number in MiSeq on PCR ampliﬁcation using genomic DNA containing SNPs. (A) The presence of a SNP in a PCR primer causes unbalanced PCR
ampliﬁcation of each allele, causing the products derived from those alleles to have diﬀerent read numbers. The two black bars represent double-stranded DNA from one allele. One
allele (bottom illustration) has the same sequence as the reference sequence (A type). The other allele (top illustration) contains a C variant in the middle and an A variant (SNP) in the
primer. During the hybridization step, a mismatch occurs at the SNP between the PCR primer and the template DNA, obstructing further PCR ampliﬁcation of the DNA containing the
SNP. The resulting PCR products could lead one to under- or overestimate the frequency of mutations. (B) How location of SNPs in PCR primers can aﬀect the detection frequency of
mutations. One allele has two mutations in the middle of the exon in the area of the PCR primer site. M1 has one mismatch in the 3′-terminal end. M2, M4, M10 have the same mismatch
but it is located in the second, fourth, and tenth positions, respectively, from the 3′-terminal end of the PCR primer. M0 does not have any mismatches in the area of the SNP in the gene-
speciﬁc primer site. One allele has a C-to-A mutation, resulting in a Thr-to-Lys substitution in exon2. Gene-speciﬁc primer pools lacking M0, M1, M2, M4, M10 were used for multiplex
PCR ampliﬁcation after completing the MiSeq procedure, and then data were analyzed by a variant caller program, Sommelier. Mismatches occurring near the 3′ terminus of primers
signiﬁcantly decrease the frequency at which mutants are detected.
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4. Conclusions
In this study, our MiSeq approach using multiplex PCR can perform
genetic testing with high sensitivity and accuracy to detect even low-
level somatic mosaic mutations that cause autoinﬂammatory diseases.
This simple procedure can be both time- and cost-eﬀective, and can be
conducted by technicians with an average skill level and without special
training. We routinely analyze several clinical DNA samples in one
MiSeq run every two weeks. This simple procedure will also minimize
inevitable human errors and guarantee the accuracy required for
diagnostic application.
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Table 2.
Variants identified in the genetic testing carried out in this study.
Genome Position* Gene Symbol CDS Level Change Protein Level Change AA Variation dbSNP Number of carriers
chr1:247582310 NLRP3** c.214 G> A Missense p. Val72Met rs117287351 2 heterozygotes
chr1:247586640 NLRP3** c.392 A >G Missense p. Lys131Arg rs188623199 1 heterozygote
chr1:247587659 NLRP3** c.914 A > C Missense p. Asp305Ala rs180177447 1 heterozygote
chr1:247588067 NLRP3** c.1322 C > T Missense p. Ala441Val rs121908146 1 heterozygote
chr1:247588442 NLRP3** c.1697 G > C Missense p. Gly566Ala 1 heterozygote
chr1:247597508 NLRP3** c.2431 G >A Missense p. Gly811Ser rs141389711 1 heterozygote
chr12:110013879 MVK c.155 G> A Missense p. Ser52Asn rs7957619 1 heterozygote
chr12:6442956 TNFRSF1A c.269 C > T Missense p. Thr90Ile rs34751757 2 heterozygotes
chr15:77310553 PSTPIP1 c.101 A > C Missense p. Lys34Thr 1 heterozygote
chr15:77324670 PSTPIP1 c.773 G> C Missense p. Gly258Ala rs34240327 2 heterozygotes
chr15:77328263 PSTPIP1 c.1106 A >G Missense p. Asp369Gly 1 heterozygote
chr16:3293405 MEFV c.2082 G >A Missense p. Met694Ile rs28940578 1 homozygote, 3heterozygotes
chr16:3297095 MEFV c.1508 C >G Missense p. Ser503Cys rs190705322 3 heterozygotes
chr16:3299462 MEFV c.1229 G >A Missense p. Arg410His 1 heterozygote
chr16:3299468 MEFV c.1223 G >A Missense p. Arg408Gln rs11466024 9 heterozygotes
chr16:3299586 MEFV c.1105 C > T Missense p. Pro369Ser rs11466023 9 heterozygotes
chr16:3304158 MEFV c.910 G> A Missense p. Gly304Arg rs75977701 3 heterozygotes
chr16:3304463 MEFV c.605 G> A Missense p. Arg202Gln rs224222 5 heterozygote
chr16:3304626 MEFV c.442 G> C Missense p. Glu148Gln rs3743930 5 homozygotes, 23 heterozygotes
chr16:3304724 MEFV c.344 C > G Missense p. Pro115Arg 2 heterozygotes
chr16:3304739 MEFV c.329 T > C Missense p. Leu110Pro rs11466018 12 heterozygotes
chr16:50753909 NOD2 c.2704 C > A Missense p. Gln902Lys 1 heterozygote
chr19:54301639 NLRP12 c.2785 G >A Missense p. Ala929Thr rs146368839 2 heterozygotes
chr19:54304482 NLRP12 c.2755 C > T Missense p. Arg919Trp rs61741349 1 heterozygote
chr19:54313707 NLRP12 c.1206 C >G Missense p. Phe402Leu rs34971363 2 heterozygotes
chr19:54327313 NLRP12 c.116 G> T Missense p. Gly39Val rs34436714 11 heterozygotes
chr6:32811629 PSMB8 c.145 C > A Missense p. Gln49Lys rs2071543, rs147533146 16 heterozygotes
* Genome position was based on human hg19 as a reference.
** In NLRP3, the clinical genetics community typically uses the second Met as the initial start site, not the ﬁrst Met. Thus, NLRP3 has two additional amino acids because the ﬁrst Met
was used for the annotation of the NLRP3 gene in this study.
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